Food-derived extracellular vesicles as delivery platforms for medicine-food homology components in metabolic syndrome.

Food Res IntAug 13, 2026 (epub)
Clinical ResearchEndocrinologyGastroenterology

Jianfeng Wang, Baoguo Sun, Lingjun Tong et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examines the role of food-derived extracellular vesicles (FDEVs) as delivery systems for medicine-food homology components (MFHCs) in managing diet-induced obesity and metabolic syndrome. The review highlights FDEVs' ability to enhance lipid metabolism, inflammatory responses, and insulin sensitivity, offering a promising approach to address these health challenges.

Key findings

  • FDEVs can efficiently deliver MFHCs to regulate lipid metabolism and inflammatory responses.
  • The review discusses the potential of FDEVs to improve insulin sensitivity in metabolic syndrome.
  • Challenges in preparation techniques and safety assessment for FDEVs are identified.

Why it matters

Understanding the potential of FDEVs as natural nanocarriers could lead to innovative strategies for treating metabolic syndrome, a significant public health concern. This approach may enhance the effectiveness of dietary interventions.

Source

PubMed · PMID 42705726

Published in Food Res Int. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.